Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Lacrimation increased, Ocular discomfort, Photophobia, SARS-CoV-2 test
Clinical narrative: Ptosis (left eye); Pain and swelling inside the eye; Pain and swelling inside the eye; Eyelid swelling; Headache (Forehead ache from increased effort needed to raise the eyelids); Fatigue; Decreased field of vision Difficulty wearing glasses; Eye strain; watery eyes; eye fatigue especially when trying to focus to see or read, digital screens are even worse; Excessive eye rubbing; Sensitivity to bright light; unfocused vision; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 49 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 27Sep2021 14:00 (Lot number: FF2588) at the age of 48 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Covid" (unspecified if ongoing), notes: If covid prior vaccination: Yes; "Known allergies: citric acid" (unspecified if ongoing). There were no concomitant medications. The following information was reported: EYELID PTOSIS (disability) with onset 30Sep2021 08:00, outcome "not recovered", described as "Ptosis (left eye)"; EYE PAIN (disability), EYE SWELLING (disability) all with onset 30Sep2021 08:00, outcome "not recovered" and all described as "Pain and swelling inside the eye"; SWELLING OF EYELID (disability) with onset 30Sep2021 08:00, outcome "not recovered", described as "Eyelid swelling"; HEADACHE (disability) with onset 30Sep2021 08:00, outcome "not recovered", described as "Headache (Forehead ache from increased effort needed to raise the eyelids)"; FATIGUE (disability) with onset 30Sep2021 08:00, outcome "not recovered", described as "Fatigue"; VISUAL IMPAIRMENT (disability) with onset 30Sep2021 08:00, outcome "not recovered", described as "Decreased field of vision Difficulty wearing glasses"; ASTHENOPIA (disability) with onset 30Sep2021 08:00, outcome "not recovered", described as "Eye strain"; LACRIMATION INCREASED (disability) with onset 30Sep2021 08:00, outcome "not recovered", described as "watery eyes"; ASTHENOPIA (disability) with onset 30Sep2021 08:00, outcome "not recovered", described as "eye fatigue especially when trying to focus to see or read, digital screens are even worse "; OCULAR DISCOMFORT (disability) with onset 30Sep2021 08:00, outcome "not recovered", described as "Excessive eye rubbing"; PHOTOPHOBIA (disability) with onset 30Sep2021 08:00, outcome "not recovered", described as "Sensitivity to bright light"; VISION BLURRED (disability) with onset 30Sep2021 08:00, outcome "not recovered", described as "unfocused vision". The events "ptosis (left eye)", "pain and swelling inside the eye", "pain and swelling inside the eye", "eyelid swelling", "headache (forehead ache from increased effort needed to raise the eyelids)", "fatigue", "decreased field of vision difficulty wearing glasses", "eye strain", "watery eyes", "eye fatigue especially when trying to focus to see or read, digital screens are even worse ", "excessive eye rubbing", "sensitivity to bright light" and "unfocused vision" were evaluated at the physician office visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: negative, notes: covid test post vaccination: covid test type post vaccination=Nasal Swab, covid test result=Negative. It was unknown if therapeutic measures were taken as a result of eyelid ptosis, eye pain, eye swelling, swelling of eyelid, headache, fatigue, visual impairment, asthenopia, lacrimation increased, asthenopia, ocular discomfort, photophobia, vision blurred. Additional information: It was also reported that the patient received second dose of BNT162B2 on 18Oct2021 14:00 (Lot number: FF2588) administered on left arm for COVID-19 immunisation. Patient had no other vaccine in four weeks and no other medications in two weeks.